Noltrexin endoprosthesis synovial fluid sterile 2 ml syringe

Mechanism of action NOLTREXIN acts by restoring the volume and viscosity of synovial fluid in the joints affected by osteoarthritis. As a result, the pain syndrome is relieved and joint mobility improves. The peculiarity of the endoprosthesis is its longer action as compared to pharmaceuticals and materials.

Biodegradation of polyacrylamide gel occurs through macrophage resorption and non-cellular lysis. Subjected to very slow biodegradation for more than 6 months. It is excreted mainly through the kidneys and liver without tissue damage. Implant metabolites (using radioactive tags) are detected in the urine and liver. Due to the safety of the drug and the practical absence of a tissue reaction, the implant does not need to be removed. The position and orientation of the implant in the joint cavity is not determined radiologically. If necessary, the implant can be removed by puncture and lavage of the joint cavity.

Indications

Deterioration of functional characteristics of joints, joint pain resulting from degenerative and traumatic changes in synovial joints affected by osteoarthritis (osteoarthritis).

Composition

Three-dimensional polyacrylamide, %: 4.00 ± 1.50; – Water, %: 96.00 ± 1.50; – Silver ions, %: 0,0001 – 0,0025.

Interaction

Concomitant use with local anesthetics, Xefocam, Diprospan, Traumeel-S or Zeel-T is possible. Action in combination with other products or drugs has not been investigated.

Directions for use

Injection of 2.5 ml to 10.0 ml into the knee joint in one to four injections of 2.5 ml at one-week intervals. Recommended technique:

• first injection of 2.5 ml or 5.0 ml,
• second 5.0 ml or 2.5 ml, depending on stage and at the discretion of the physician.

Pelvic joint: two injections of 2.5 ml or one injection of 5.0 ml. The recommended interval between injections is one week.

The method of administration is calculated individually depending on the stage of osteoarthritis and at the discretion of the physician.

The multiple injections into the knee joint while the patient is seated have the potential to damage the cartilage covering the articular surfaces and menisci with a large-diameter needle.

In order to avoid overfilling the joint with dense, slowly resorbable material, it is recommended that the course be discontinued when the clinical result is good!

Courses should be repeated every 6 to 24 months depending on clinical manifestations.

The repeat course of injections may be shortened as indicated.

In other joints, the endoprosthesis is injected at 2.5 ml or less, depending on the size of the joint.

Special Instructions

The treatment procedure is similar to other intraarticular injections with minimal risk of complications (inflammation, arthralgia, internal bleeding due to vascular trauma).

Perform normal precautions: the prosthesis may only be injected in a clean dressing room or operating room by qualified medical personnel. Keep out of the reach of children!

Synopsis

Endoprosthesis of synovial fluid NOLTREXIN sterile in a single-use syringe (hereinafter referred to as endoprosthesis or NOLTREXIN). High viscosity, high molecular gelatinous polymer, transparent to light yellow in color, sterile. NOLTREXIN is a synthetic material for endoprosthesis and correction of viscoelastic properties of synovial joint fluid. It does not contain any substances of animal origin. Due to the high density of the gel a small amount of bubbles in the syringe volume is acceptable.

Side effects

After administration of NOLTREXIN a burning sensation in the joint may occur. The average duration of the pain syndrome is 12 – 24 hours, but not more than 3 days. The pain syndrome is stopped by taking analgesics or non-steroidal anti-inflammatory drugs (the course is prescribed individually by the attending physician) or it passes on its own.